« Return to News | R&D Trends

Neurelis, Biotie Therapies partners, with acquisition option

Thursday, June 6, 2013 01:46 PM

Pharmaceutical company Neurelis has signed an agreement with Biotie Therapies, a specialized drug development company, to develop intranasal diazepam (NRL-1) and provide Biotie with the exclusive option, but not the obligation, to acquire all outstanding shares of Neurelis.

Biotie will pay $1 million to Neurelis for the exclusive option to acquire all outstanding shares of Neurelis. During the option period, Biotie will conduct the development program for NRL-1 and work with Neurelis to advance the program with the FDA in preparation for the NDA submission. If the option is exercised and the merger consummated, Biotie will pay $8.75 million, subject to certain adjustments, in new ordinary shares of Biotie. Stockholders of Neurelis also will be eligible to receive additional milestone payments based on certain regulatory and commercial milestones.

NRL-1 is a proprietary formulation of diazepam delivered via a commercially available nasal sprayer.  It is being developed for patients who require intermittent use of diazepam to control bouts of acute repetitive seizure activity. 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.